https://www.selleckchem.com/pr....oducts/chitosan-olig
These modifications aim to improve initial responses to therapy and enhance the durability of response. Furthermore, CAR T cells can deliver these molecules locally to the tumor microenvironment, avoiding systemic distribution. This approach has been tested in preclinical models using a variety of different classes of agonistic and antagonistic proteins, and clinical trials are currently underway to assess efficacy in patients. Chimeric antigen receptor T therapy has heralded a new era in the treatment of acute lymphobl
Like
Comment
Share
